A Multi-center, Randomized, Double-Blind, Active-controlled, Phase3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Enavogliflozin (Primary) ; Dapagliflozin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 30 Mar 2022 Status changed from not yet recruiting to completed.
- 09 Dec 2020 New trial record